IBIO, INC. Cash and Cash Equivalents, Period Increase (Decrease)
IBIO, INC. (IBIO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$6.90 million for the 9-month period ending 2019-03-31, per its 10-Q filed 2019-05-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-10
- IBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$4.32M.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$2.65M, a 290.03% decline year-over-year.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $76.00K.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $12.54M.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $7.85M.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$14.93M, a 210.40% decline from fiscal 2016.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $13.52M, a 129.00% increase from fiscal 2015.
- IBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $5.90M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | -$4.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-10 | -$6.97M derived: sum of 2 quarters · filed 2019-05-10 | -$6.90M 10-Q · filed 2019-05-10 | $5.64M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-12-31 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | -$2.57M 10-Q · filed 2019-02-13 | $9.96M derived: sum of 3 quarters · filed 2019-02-13 | $6.05M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-09-30 | $76.00K 10-Q · filed 2018-11-13 | $12.61M derived: sum of 2 quarters · filed 2018-11-13 | $8.70M derived: sum of 3 quarters · filed 2019-05-10 | $10.09M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-06-30 | $12.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-18 | $8.62M derived: sum of 2 quarters · filed 2019-05-10 | $10.02M derived: sum of 3 quarters · filed 2019-05-10 | $7.85M 10-K · filed 2018-09-18 | ||||
| 2018-03-31 | -$3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-10 | -$2.52M derived: sum of 2 quarters · filed 2019-05-10 | -$4.69M 10-Q · filed 2019-05-10 | -$9.02M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | -$778.00K 10-Q · filed 2019-02-13 | -$5.11M derived: sum of 3 quarters · filed 2019-02-13 | -$9.02M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-09-30 | -$2.17M 10-Q · filed 2018-11-13 | -$6.51M derived: sum of 2 quarters · filed 2018-11-13 | -$10.41M derived: sum of 3 quarters · filed 2018-11-13 | -$14.18M derived: sum of 4 quarters · filed 2018-11-13 | ||||
| 2017-06-30 | -$4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-18 | -$8.24M derived: sum of 2 quarters · filed 2018-09-18 | -$12.01M derived: sum of 3 quarters · filed 2018-09-18 | -$14.93M 10-K · filed 2018-09-18 | ||||
| 2017-03-31 | -$3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-11 | -$7.68M derived: sum of 2 quarters · filed 2018-05-11 | -$10.59M 10-Q · filed 2018-05-11 | -$9.47M derived: sum of 4 quarters · filed 2018-05-11 | ||||
| 2016-12-31 | -$3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-14 | -$6.68M 10-Q · filed 2018-02-14 | -$5.56M derived: sum of 3 quarters · filed 2018-02-14 | $9.60M derived: sum of 4 quarters · filed 2018-02-14 | ||||
| 2016-09-30 | -$2.92M 10-Q · filed 2017-11-09 | -$1.79M derived: sum of 2 quarters · filed 2017-11-09 | $13.37M derived: sum of 3 quarters · filed 2017-11-09 | $11.71M derived: sum of 4 quarters · filed 2017-11-09 | ||||
| 2016-06-30 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-15 | $16.28M derived: sum of 2 quarters · filed 2017-09-15 | $14.63M derived: sum of 3 quarters · filed 2017-09-15 | $13.52M 10-K · filed 2017-09-15 | ||||
| 2016-03-31 | $15.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | $13.51M derived: sum of 2 quarters · filed 2017-05-15 | $12.40M 10-Q · filed 2017-05-15 | $13.81M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-21 | -$2.76M 10-Q · filed 2017-02-21 | -$1.35M derived: sum of 3 quarters · filed 2017-02-21 | -$631.00K derived: sum of 4 quarters · filed 2017-02-21 | ||||
| 2015-09-30 | -$1.11M 10-Q · filed 2016-11-18 | $304.00K derived: sum of 2 quarters · filed 2016-11-18 | $1.02M derived: sum of 3 quarters · filed 2016-11-18 | $4.90M derived: sum of 4 quarters · filed 2016-11-18 | ||||
| 2015-06-30 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | $2.13M derived: sum of 2 quarters · filed 2016-10-13 | $6.01M derived: sum of 3 quarters · filed 2016-10-13 | $5.90M 10-K · filed 2016-10-13 | ||||
| 2015-03-31 | $717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-23 | $4.59M derived: sum of 2 quarters · filed 2016-05-23 | $4.49M 10-Q · filed 2016-05-23 | $3.75M derived: sum of 4 quarters · filed 2016-05-23 | ||||
| 2014-12-31 | $3.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-22 | $3.77M 10-Q · filed 2016-02-22 | $3.03M derived: sum of 3 quarters · filed 2016-02-22 | $1.69M derived: sum of 4 quarters · filed 2016-02-22 | ||||
| 2014-09-30 | -$104.00K 10-Q · filed 2015-11-13 | -$847.00K derived: sum of 2 quarters · filed 2015-11-13 | -$2.19M derived: sum of 3 quarters · filed 2015-11-13 | $42.00K derived: sum of 4 quarters · filed 2015-11-13 | ||||
| 2014-06-30 | -$743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-13 | -$2.09M derived: sum of 2 quarters · filed 2015-10-13 | $146.00K derived: sum of 3 quarters · filed 2015-10-13 | -$824.00K 10-K · filed 2015-10-13 | ||||
| 2014-03-31 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $889.00K derived: sum of 2 quarters · filed 2015-05-15 | -$81.00K 10-Q · filed 2015-05-15 | $2.81M derived: sum of 4 quarters · filed 2015-05-15 | ||||
| 2013-12-31 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-24 | $1.26M 10-Q · filed 2015-02-24 | $4.15M derived: sum of 3 quarters · filed 2015-02-24 | $2.86M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-09-30 | -$970.00K 10-Q · filed 2014-11-14 | $1.92M derived: sum of 2 quarters · filed 2014-11-14 | $625.00K derived: sum of 3 quarters · filed 2014-11-14 | -$832.00K derived: sum of 4 quarters · filed 2014-11-14 | ||||
| 2013-06-30 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | $1.59M derived: sum of 2 quarters · filed 2014-09-29 | $138.00K derived: sum of 3 quarters · filed 2014-09-29 | -$1.21M 10-K · filed 2014-09-29 | ||||
| 2013-03-31 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-15 | -$2.75M derived: sum of 2 quarters · filed 2014-05-15 | -$4.10M 10-Q · filed 2014-05-15 | -$4.10M 10-Q · filed 2013-05-20 | -$5.20M derived: sum of 4 quarters · filed 2014-05-15 | |||
| 2012-12-31 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14 | -$2.81M 10-Q · filed 2014-02-14 | -$2.81M 10-Q · filed 2013-02-19 | -$3.90M derived: sum of 3 quarters · filed 2014-02-14 | $2.20M derived: sum of 4 quarters · filed 2014-02-14 | |||
| 2012-09-30 | -$1.35M 10-Q · filed 2013-11-14 | -$1.35M 10-Q · filed 2012-11-14 | -$2.45M derived: sum of 2 quarters · filed 2013-11-14 | $3.65M derived: sum of 3 quarters · filed 2013-11-14 | $2.75M derived: sum of 4 quarters · filed 2013-11-14 | |||
| 2012-06-30 | -$1.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2013-10-04 | $5.00M derived: sum of 2 quarters · filed 2013-10-04 | $4.10M derived: sum of 3 quarters · filed 2013-10-04 | $2.78M 10-K/A · filed 2013-10-04 | $2.78M 10-K/A · filed 2012-10-15 | |||
| 2012-03-31 | $6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-20 | $5.20M derived: sum of 2 quarters · filed 2013-05-20 | $3.88M 10-Q · filed 2013-05-20 | $2.89M derived: sum of 4 quarters · filed 2013-05-20 | ||||
| 2011-12-31 | -$899.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-19 | -$2.22M 10-Q · filed 2013-02-19 | -$3.21M derived: sum of 3 quarters · filed 2013-02-19 | -$5.15M derived: sum of 4 quarters · filed 2013-02-19 | ||||
| 2011-09-30 | -$1.32M 10-Q · filed 2012-11-14 | -$2.31M derived: sum of 2 quarters · filed 2012-11-14 | -$4.25M derived: sum of 3 quarters · filed 2012-11-14 | $1.21M derived: sum of 4 quarters · filed 2012-11-14 | ||||
| 2011-06-30 | -$992.84K derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-10-15 | -$2.93M derived: sum of 2 quarters · filed 2012-10-15 | $2.53M derived: sum of 3 quarters · filed 2012-10-15 | $1.93M 10-K/A · filed 2012-10-15 | ||||
| 2011-03-31 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $3.52M derived: sum of 2 quarters · filed 2012-05-15 | $2.93M 10-Q · filed 2012-05-15 | |||||
| 2010-12-31 | $5.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | $4.86M 10-Q · filed 2012-02-14 | ||||||
| 2010-09-30 | -$596.11K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |